Seven in 10 women with early breast cancer do not need chemotherapy, study finds
BMJ 2018; 361 doi: https://doi.org/10.1136/bmj.k2473 (Published 04 June 2018) Cite this as: BMJ 2018;361:k2473- Susan Mayor
- Chicago, USA
Most women with early stage hormone receptor positive breast cancer do not benefit from chemotherapy on top of endocrine therapy after surgery if tests show they have a mid-range risk of recurrence, a large randomised trial has reported.1
“Half of all breast cancers are hormone receptor positive, HER2 negative, and axillary node negative. Our study shows that chemotherapy may be avoided in about 70% of these women when its use is guided by the 21 gene recurrence score, so limiting chemotherapy to the 30% who we …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.